Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 2/20 | 0.34 |
| ▸ | RARB | P10826 | 2/20 | 0.34 |
| ▸ | RARG | P13631 | 2/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766888 | 0.82 | RARA (0.40) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL9077146 | 0.81 | RARB (0.54) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL8766766 | 0.81 | RARB (0.47) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL8766757 | 0.80 | PTGDR (0.38) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL5827697 | 0.79 | RARA (0.50) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL8766282 | 0.75 | RARB (0.53) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL8766289 | 0.75 | RARB (0.53) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL404791 | 0.74 | HDAC11 (0.36) | RARARARBRARGNPY1RNPY2R | |
| SCHEMBL6619470 | 0.74 | PTGDR2 (0.42) | PTGDRPTGDR2RARARARBRARG | |
| SCHEMBL8766206 | 0.72 | RARB (0.73) | RARARARBRARGKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463718-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | Incyte San Diego Incorporated (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
| WO-2003050098-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | INCYTE SAN DIEGO INCORPORATED (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0584191-B1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | CIRD GALDERMA (FR) | 1997-08-13 | — | — | EP | disclosed |
| US-5547983-A | Aromatic and polycyclic compounds and their use in human or veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | PTGDR 1332/4885PTGDR2 934/4885RARA 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.